Nanobiotechnological modification of hemoglobin and enzymes from this laboratory

Thomas Ming Swi Chang*

Artificial Cells & Organs Research Centre of the Departments of Physiology, Medicine & Biomedical Engineering, Faculty of Medicine, McGill University, 3655, Drummond Street, Montreal, Quebec, Canada H3G 1Y6

Abstract

Polyhemoglobin is formed by the nanobiotechnological assembling of hemoglobin molecules into soluble nanodimension complex. A further step involves the nanobiotechnological assembly of hemoglobin, catalase and superoxide dismutase into a soluble nanodimension complex. This acts both as oxygen carrier and antioxidant to prevent the oxidative effects of hemoglobin. A further step is the preparation of nanodimension artificial red blood cells that contain hemoglobin and all the enzymes present in red blood cells. Other approaches include a polyhemoglobin–fibrinogen that acts as an oxygen carrier with platelet-like activity, and a polyhemoglobin–tyrosinase to retard the growth of a fatal skin cancer, melanoma.

Keywords

Nanobiotechnology; Hemoglobin; Polyhemoglobin; Catalase; Superoxide dismutase; Nanomedicine; Blood substitutes; Fibrinogen; Tyrosinase; Melanoma

1. Introduction

Nanotechnology is a collective term that refers to technological developments on the nanometer scale, usually 0.1–100 nm. This covers many areas including nanobiotechnology. Initially this refers to nanobioparticles. However, since many biological molecules like proteins are of nanoparticle dimensions, more detailed definitions are used by workers in this area. This includes the definition that nanobiotechnology is the assembling of biological molecules into 1 to 100-nanometer dimensions. These dimensions can be the diameter of nanodimension artificial cells or particles; membranes with nanodimension thickness or nanotubules with nanodimension diameter. There are different approaches for the nanobiotechnological assembling of proteins. The first nanobiotechnological approach reported in the literature is the cross-linking of Hb into ultrathin polyHb (PolyHb) membrane of nanodimension thickness for artificial cell membrane [1,2]. If the emulsion is made even smaller, then the whole artificial cells with its Hb can be cross-linked into PolyHb of nanodimension. Glutaraldehyde can cross-link Hb into soluble PolyHb of

*Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, 3655 Drummond Street, Montreal, Quebec, Canada H3Y1Y6. artcell.med@mcgill.ca. URL:<http://www.artcell.mcgill.ca>.

nanodimension [3]. Nanodimension artificial cells containing Hb can also be formed in the form of lipid vesicles containing Hb or nanodimension biodegradable polymeric membrane artificial cells containing Hb [4,5].

2. Cross-linking of Hb into PolyHb

2.1. Basic principles

Hb is a tetramer with two α subunits and two β subunits ($\alpha_1\beta_1\alpha_2\beta_2$) [6]. When Hb is infused into the body, the tetramer ($\alpha_1\beta_1\alpha_2\beta_2$) breaks down into toxic dimers ($\alpha_1\beta_1$ and $\alpha_2\beta_2$) that cause renal toxicity and other adverse effects. Even in the form of tetramers, Hb molecules can cross the intercellular junction of blood vessels to cause adverse vasopressor effects. We have used the principle of nanobiotechnology to assemble Hb molecules into nanodimension polyHb [1–3]. For example, bifunctional agents can cross-link the reactive amino groups of Hb to assemble Hb molecules into polyHb (polyHb). Sebacyl chloride was the first bifunctional agent used to form membrane of nanodimension thickness [1,2].

Another bifunctional agent, glutaraldehyde was the first to be used to cross-link Hb and trace amount of CAT into soluble nanodimension structure [3].

In the glutaraldehyde procedure, cross-linking is adjusted so that the cross-linked PolyHb is in a soluble state. This cross-links protein molecules to one another (intermolecular). It can also cross-link the protein internally (intramolecular).

2.2. Tetrameric Hb in polyHb

In order not to cause adverse vasopressor effects, polyHb preparation must contain less than 2% of tetrameric Hb. Otherwise, infusion can result in vasopressor effects as the tetramer crosses the intercellular junctions of blood vessels to bind nitric oxide needed for normal vasoactivity. This cannot be done just by increasing the degree of polymerization alone since this would result in very large polyHb that are not stable in solution. The solution is to use suitable polymerization condition to prepare polyHb containing about 10% of tetramers. The tetramers are then removed by size exclusion chromatography and filtration using plasmapheresis membranes [4].

2.3. Immunological properties of polyHb

Even though Hb is only weakly antigenic, one has to make sure that the cross-linking of Hb into polyHb does not enhance its immunogenicity. In order to test this we analyzed the in-vitro and in-vivo immunogenicity of cross-linking Hb into polyHb [4]. Repeated subcutaneous injections of rat Hb in Freud's adjuvant into rats did not increase the antibody

titers. Even in the polymerized form (PolyHb) there is no increase in antibody titers using the very severe test of Freud's adjuvant. Infusion of polyHb from the same species either for the first time or under the most severe immunization condition, did not result in any adverse response. On the other hand, Hb from another species (heterologous) is slightly antigenic resulting in a very small but significant increase in antibody titer. Cross-linking Hb from another species into PolyHb results an increase in antigenicity. However, even heterologous polyHb showed much lower antigenicity when compared with albumin. Infusion of polyHb from a different species for the first time also did not result in any adverse response. However, when heterologous polyHb is infused after the most severe immunization procedures, there are immunological reactions. Thus, the result seems to show that polyHb from the same species would not have any immunological problems. It also shows that polyHb from a difference species also did not produce adverse effect when infused for the first time. This finding is supported by another group in actual clinical trials using large volumes of bovine PolyHb showing no adverse clinical immunology effects in humans. What one cannot conclude from these results is how often can polyHb from another species be infused before there is an immunological problem.

2.4. Complement activation of human plasma as an in-vitro screening test

Response in animals is not always the same as for humans. This is especially in tests for hypersensitivity, complement activation and immunology. We have devised a simple in-vitro test tube screening tests to bridge the gap between animal safety studies and use in humans [4]. This consists of adding 0.1 ml of modified Hb to a test tube containing 0.4 ml of human plasma or blood. Then analyze the plasma for complement activation of C3 to C3a after incubating for 1 h. The use of human plasma or blood gives the closest to human response next to actual injection. If we want to be more specific, we can use the plasma of the same patient who is to receive the blood substitute.

Fig. 1 summarizes those factors that initiate alternate and classical pathways leading to complement activation of C3 to C3a. Modified Hb may be contaminated with trace amount of blood group antigen that can form antigen-antibody complex that can activate C3 [4]. Others include endotoxin, microorganism, insoluble immune-complexes, chemicals, polymers, organic solvents and others [4]. In the preparation or production of blood substitute, different chemicals, reagents and organic solvents are used. This includes cross-linkers, lipids, solvents, chemicals, polymers and other materials. Some of these can potentially result in complement activation and other reactions in humans. Other potential sources of problems that can be screened include trace contaminants from ultrafilters, dialysers and chromatography [4].

2.5. Present status of PolyHb in clinical trials

Gould's group has carried out Phase III clinical trials on 171 patients and has shown that this product can successfully compensate for extensive blood loss in trauma surgery by maintaining the Hb level at the 8 to 10 g/dl needed for safe surgery with no reported side effects [7]. For example, transfusion of this polyHb in patients with Hb level as low as 2 g/dl can raise the Hb level to within the 8 to 10 g/dl level with the patients recovering from surgery. Normally patients with Hb levels of <3% do not survive. Gould's has infused up to

10 l of polyHb into individual trauma surgery patients. In the USA this product has been approved for compassionate use in patients and it is waiting for regulatory decision for routine clinical uses.

Given that the supply of Hb from outdated donor blood is limited, a glutaraldehyde-cross-linked bovine polyHb has been developed and tested in Phase III clinical trials [8]. For example, they have carried out a multicenter, multinational, randomized, single-blind, and RBC-controlled Phase III clinical trial in patients undergoing elective orthopedic surgery. A total of 688 patients were randomized 1:1 to receive either the polyHb or RBC at the time of the first perioperative RBC transfusion decision and 59.4% of the patients receiving polyHb required no RBC transfusion all the way to follow up and 96.3% avoided transfusion with RBC on the first postoperative day and up to 70.3% avoided RBC transfusion up to 7 days after. In North America, this polyHb has been approved for compassionate uses in patients.

3. Biotechnology of assembling Hb with catalase and superoxide dismutase

3.1. Rationales

PolyHb is likely to have an important role in certain clinical applications. However, for conditions with potentials for ischemia reperfusion injuries we have to take into consideration the issue of oxygen radicals [4,9,10]. Our aim is therefore to use nanobiotechnology to assemble Hb with CAT and superoxide dismutase into nanodimension PolyHb-CAT-SOD that combines oxygen carrying function with the ability to remove oxygen radicals. Human superoxide dismutase and catalase are available in the recombinant form and safe for use in humans. However, a heterologous source of these enzymes may result in immunological reactions.

3.2. Method of preparation

Typically, each gram of Hb is cross-linked with 3000 U of SOD and 300,000 U of CAT [4,9]. The ratio of Hb to SOD and CAT (in mg/ml) is 1:0.009:0.0045. This amount of enzymes results in minimal change in the relative amount of Hb. Thus, there is minimal change in the oxygen carrying capacity of the PolyHb-CAT-SOD when compared to polyHb. The ratio of enzyme can be varied over a very wide range, thus much higher amount of enzymes can be included when needed. [4,9]. During the cross-linking process, there is minimal formation of metHb when cross-linking Hb with SOD and CAT [4]. However, when cross-linking is carried out with Hb alone, there is marked formation of metHb during the preparative procedure. This shows that cross-linking Hb with SOD and CAT may also provide oxidative protection during the preparation of polyHb.

3.3. Molecular characterization of PolyHb-CAT-SOD

Only trace amounts of antioxidant enzymes are used in relation to Hb. The ratio of Hb to SOD and CAT (as mg/ml) is typically 1:0.009:0.0045. Only 5% of the enzyme is not cross-linked into the PolyHb-CAT-SOD [11] (Table 1). There is no CAT or SOD enzyme activity in the PolyHb prepared from ultrapure Hb. Cross-linking CAT, SOD and Hb with a glutaraldehyde: Hb molar ratio of 8:1 retains 90% of SOD activity and 99% of CAT activity. A higher molar ratio of 16:1 leads to a slightly lower enzyme activity of 95%.

3.4. Oxygen dissociation curve

Fig. 2 summarizes the results of the oxygen dissociation analysis for the 24-hour cross-linked polyHb ($n=6$), the 24-hour cross-linked PolyHb-SOD-CAT ($n=6$) and the ultrapure Hb ($n=6$). The P_{50} for polyHb is 26.1 ± 0.2 mmHg, while that of PolyHb-SOD-CAT is 24.7 ± 0.2 mmHg and ultrapure Hb is 27.8 ± 0.0 mmHg.

3.5. Effects of oxidative challenge on the degradation of Hb in PolyHb and PolyHb-CAT-SOD

Oxygen radicals can oxidize the Fe^{2+} -heme component of Hb to Fe^{3+} -heme that can stimulate the production of superoxide ($\text{O}_2^{\bullet-}$) [9]. Furthermore, excessive oxidative damage to Hb leads to the release of iron from heme. In the presence of free iron, $\text{O}_2^{\bullet-}$ and H_2O_2 rapidly react to produce hydroxyl radical ($\bullet\text{OH}$) (ie. Fenton reaction).

Hydrogen peroxide can also react with Hb to produce ferrylHb. These can promote cellular injury by reacting with carbohydrates, nucleic acids, and proteins. These reactive species can also readily abstract methylene hydrogen from polyunsaturated fatty acids resulting in lipid peroxidation. We carried out the following studies to see if PolyHb-CAT-SOD can prevent these effects on PolyHb.

3.6. Oxidative effects on methemoglobin formation

We use absorbance spectra to follow the effects of superoxide and hydrogen peroxide on the Hb components of PolyHb and PolyHb-CAT-SOD [9]. For PolyHb increase in methHb (Fe^{3+}) is shown as a stepwise increase at the absorbance peak of 630 nm. PolyHb-CAT-SOD with a SOD/CAT ratio of 0.01 prevents this oxidation, while a SOD/CAT ratio of 100 produces no protective effect. In a typical study (Fig. 3), hydrogen peroxide is added to PolyHb (10 mM) or PolyHb-SOD-CAT (10 mM), and the absorbance spectra (450–700 nm) followed. For PolyHb, the spectral changes reflect the oxidation of ferrous (Fe^{2+})-heme to ferric (Fe^{3+})-heme (Fig. 3 AB). The rate of degradation increases with increases in hydrogen peroxide added in amounts from 10 to 100 to 500 μM . The absorbance spectra of PolyHb-CAT-SOD are minimally affected, indicating that these reactions are minimized due to the elimination of H_2O_2 (Fig. 3 CD). Similar results are observed following oxidative challenge with exogenous superoxide ($\text{O}_2^{\bullet-}$) produced from xanthine/xanthine oxidase.

3.7. The oxidative release of iron

The oxidative challenges on iron release from PolyHb and PolyHb-CAT-SOD were analyzed. PolyHb (15 μM) or PolyHb-SOD-CAT (15 μM) are incubated with different concentrations of H_2O_2 for 1 h at 37 °C. We use the Ferrozine assay method [13] to measure release of iron. For PolyHb the addition of H_2O_2 leads to the release of up to 37% of the total iron in PolyHb (Fig. 4). On the other hand, for PolyHb-CAT-SOD less than 1% is

released over the same H_2O_2 (Fig. 4). It is important to note that decreasing the amount of CAT cross-linked to the PolyHb-CAT-SOD decreases the protective effects on the release of iron during H_2O_2 incubation.

3.8. Lipid peroxidation and salicylate hydroxylation

Adding 50 μM or 500 μM of hydrogen peroxide to PolyHb in the presence of lipid resulted in very significant increases in lipid peroxidation as shown by the production of malondialdehyde. On the other hand, the addition of 500 μM of hydrogen peroxide to PolyHb-SOD-CAT causes significantly less lipid peroxidation [9]. Similarly, the addition of 500 μM of hydrogen peroxide to PolyHb causes salicylate hydroxylation as shown by the product 2,5 dihydroxybenzoate. However, this does not happen for PolyHb-SOD-CAT.

3.9. Ischemia reperfusion injury

In prolonged and severe hemorrhagic shock, stroke, myocardial infarction, donor organs for transplantation and other conditions there is insufficient supply of oxygen resulting in ischemia. Ischemia stimulates the production of hypoxanthine. When the tissue is again perfused with oxygen, reperfusion, hypoxanthine is converted into superoxide. By several mechanisms, superoxide results in the formation of oxygen radicals that can cause tissue injury. Our animal studies show that PolyHb-CAT-SOD, unlike PolyHb, does not cause the release of oxygen radicals or ischemia reperfusion injury in conditions of ischemia reperfusion. Detailed results of these studies are available elsewhere [4,11]. Briefly, in the form of PolyHb-CAT-SOD the enzymes stay in the circulation with a half time of 24 h. This is unlike the rapid removal of free SOD and CAT from the circulation (10 and 20 min., respectively). Furthermore, unless cross-linked to Hb, these enzymes are not located in close proximity to Hb, and thus are less likely to give adequate protection to Hb initiated oxygen radicals. The attenuation in hydroxyl radical generation with PolyHb-SOD-CAT shows promise for its potential role as a protective therapeutic agent in clinical situations of ischemia and oxidative stress as in stroke, myocardial infarction, sustained severe hemorrhagic shock, organ transplantation and in cardiopulmonary bypass.

4. Artificial RBCs

The first artificial RBCs prepared in 1957 by microencapsulation of hemolysate have oxygen dissociation curve similar to RBCs [14]. We continued to study a number of microcapsule membranes including cellulose, silicone rubber, 1,6-hexamethylenediamine, cross-linked protein, phospholipid-cholesterol complexes on cross-linked protein membrane or polymer [1,2]. However, these artificial RBCs, even with diameters of down to 1 μm , survived for a short time in the circulation after intravenous injections. Our study shows that the long circulation time of RBCs is due to the presence of neuraminic acid on the membrane [2]. This led us to study the effects of changing surface properties of the artificial RBCs [2]. This has resulted in significant increases in circulation time, but still not sufficient for clinical uses.

5. Hb lipid vesicles

5.1. Lipid membrane artificial cell

We prepared larger artificial cells with lipid membrane by supporting the lipid in the form of lipid–protein membrane and lipid–polymer membrane [2]. Others later reported the preparation of submicron 0.2 μm diameter artificial RBC using lipid membrane vesicles to encapsulate Hb [15]. This increased the circulation time significantly, although the circulation time was still rather short. Many investigators have since carried out research to improve the preparation and the circulation time. The most successful approach to improve the circulation time is to incorporate polyethylene glycol (PEG) into the lipid membrane artificial RBC resulting in a circulation half time of more than 30 h [16]. Another important group has for many years carried out extensive research and development and commercial development and preclinical animal studies. Their extensive studies are available in their many publications and reviews [17,18].

6. Biodegradable polymeric nanodimension artificial RBCs

6.1. Introduction

We have used a biodegradable polymer, polylactic acid (PLA), for the microencapsulation of Hb, enzymes and other biologically active material since 1976 [19]. More recently, we started to prepare artificial RBCs of 100 nm mean diameter using PLA, PEG-PLA membrane and other biodegradable polymers [20–22].

6.2. Characteristics

A typical electron micrograph for the biodegradable polymer Hb nanocapsules prepared with D,L-PLA shows that they are spherical and homogeneous. Their diameter ranges from 40 to 120 nm with a mean diameter of 80 nm. The membrane thickness is 5–15 nm. We have replaced most of the 6 g/dl of lipid membrane in Hb lipid vesicles with 1.6 g/dl of biodegradable polymeric membrane material. This marked decrease in the lipid component would lessen effects on the RES and lessen lipid peroxidation in ischemia reperfusion.

6.3. Properties of Hb

We can increase the Hb content in the PLA nano artificial cell suspension from 3 g/dl to 15 g/dl (same as whole blood). This has normal P_{50} , Hill's coefficient and Bohr coefficients. The characteristics of the preparation containing 10.97 g/dl of Hb prepared with D,L-PLA is listed in Table 2. Nanocapsules can be prepared with up to 15 g/dl Hb concentration.

We used the TCS Hemoxanalyzer (TCS Medical Products Co., U.S.A.) to measure oxygen affinity for PLA artificial RBC with 10.97 g/dl Hb. There is no significant difference between Hb nano artificial RBC and the original bovine Hb used for the preparation. Hill coefficient is 2.4 to 2.9. These results show that the procedure of preparation of PLA nano artificial RBCs does not have adverse effects on the Hb molecules. In the physiological pH range, oxygen affinity of PLA nano artificial RBC changed with pH and the Bohr effect is -0.22 to -0.24 [20–22].

6.4. Enzymes and multienzymes

We have earlier carried out basic research on artificial cells containing multienzyme systems with cofactor recycling [24]. A number of enzymes like carbonic anhydrase, CAT, superoxide dismutase and the metHb reductase system, normally present in RBC have been encapsulated within nano artificial RBC and retain their activities [4]. For example we have encapsulated the RBC metHb reductase system into the nano artificial RBC and showed that this can convert metHb to Hb. For PLA nano artificial RBC, the membrane can be made permeable to glucose and other small molecules. This allows us to prepare nano artificial RBC containing the metHb reductase system to function as shown in Fig. 5. Unlike lipid membrane, biodegradable polymeric membrane is permeable to glucose. Thus, the inclusion of RBC enzymes prevents MetHb formation even at 37 °C and we can also convert MetHb to Hb at 37 °C. In addition, unlike lipid membrane, the nanocapsule membrane allows plasma factors like ascorbic acid to enter the nanocapsules to prevent MetHb formation (Fig. 5).

6.5. Circulation time

In order to increase the circulation time, we synthesized a new PEG-PLA copolymer for the artificial RBC membrane [23]. After extensive research, we now have a circulation time in rats that is double that of glutaraldehyde cross-linked PolyHb. Thus, after a 30% blood volume toploading using polyHb (10 g/dl), the best polyHb can only attain a maximal Hb concentration of 3.35 g/dl. The best PEG-PLA artificial RBC, on the other hand, can reach a maximal Hb concentration of 3.60 g/dl. Since the RES in rats is much more efficient in removing particulate matter when compared to those in humans, it is likely that the half time would be longer in humans.

6.6. Other directions for PolyHb

The above review only includes some examples to show the use of nanobiotechnology for the modification of hemoglobin and enzymes. This principle can be extended to other systems. For example, we have prepared soluble nanodimension complex of PolyHb–fibrinogen [25] that carries oxygen and at the same time has platelet-like activities. Another example is our study of another soluble nanodimension of PolyHb–tyrosinase [26]. This has the combined function of lowering systemic tyrosine to retard the growth of a fatal skin cancer, melanoma. Many other extensions and modifications of this general principle in nanobiotechnology are possible. Other groups have also carried out different approaches that are not detailed in this paper that is an overview of research being carried out in this laboratory. For example, Bucci's group has developed novel zero-link polymers of hemoglobin, which do not extravasate and do not induce pressure increases upon infusion[27]. Olsen's group has synthesized a hemoglobin polymer containing antioxidant enzymes using complementary chemistry of maleimides and sulfhydryls[28].

Acknowledgments

The author acknowledges the ongoing research grants from the Canadian Institutes of Health Research and the Quebec Ministry of Health's Hemovigilance Program in the form of a FRSQ Research Group (d'équip) on Blood Substitutes in Transfusion Medicine.

Abbreviations

Hb	Hemoglobin
MetHb	metHb
PEG	polyethylene glycol
PLA	polylactide
PolyHb	polyHb
RBC	red blood cells
CAT	catalase
SOD	superoxide dismutase
RES	Reticuloendothelial system

References

1. Chang TMS. Semipermeable microcapsules. *Science*. 1964; 146(3643):524. [PubMed: 14190240]
2. Chang, TMS. *Artificial Cells*. Monograph, Charles C. Thomas; Springfield, IL: 1972. (Full text available at www.artcell.mcgill.ca)
3. Chang TMS. Stabilisation of enzymes by microencapsulation with a concentrated protein solution or by microencapsulation followed by cross-linking with glutaraldehyde. *Biochem Biophys Res Commun*. 1971; 44(6):1531–1536.
4. Chang, TMS. Monograph on “ARTIFICIAL CELLS: Biotechnology, Nanotechnology, Blood Substitutes, Regenerative Medicine, Bioencapsulation, Cell/Stem Cell Therapy”. World Science Publisher; 2007. p. 452
5. Chang, TMS. *Blood Substitutes: Principles, Methods, Products and Clinical Trials*. Vol. 1. Basel Karger; 1997. (Full text and updates available for free online viewing at www.artcell.mcgill.ca)
6. Perutz MF. Myoglobin and Hb: role of distal residues in reactions with haem ligands. *Trends Biochem Sci*. 1989; 14:42–44. [PubMed: 2650040]
7. Gould SA, et al. The life-sustaining capacity of human polymerized Hb when red cells might be unavailable. *J Am Coll Surg*. 2002; 195:445–452. [PubMed: 12375748]
8. Pearce, LB., Gawryl, MS., Rentko, VT., Moon-Massat, PF., Rausch, CW. HBOC-201 (Hb Glutamer-250 (Bovine), hemopure): clinical studies. In: Winslow, R., editor. *Blood Substitutes*. Academic Press; San Diego: 2006. p. 437-450.
9. D’Agnillo F, Chang TMS. PolyHb-superoxide dismutase. Catalase as a blood substitute with antioxidant properties. *Nat Biotechnol*. 1998; 16(7):667–671. [PubMed: 9661202]
10. Alayash AI. Oxygen therapeutics: can we tame Hb. *Nat Rev Drug Discov*. 2004; 3:152–159. [PubMed: 15043006]
11. Powanda D, Chang TMS. Cross-linked polyHb-superoxide dismutase-catalase supplies oxygen without causing blood brain barrier disruption or brain edema in a rat model of transient global brain ischemia–reperfusion. *Artif Cells Blood Substit Immobil Biotechnol Int J*. 2002; 30:25–42.
12. D’Agnillo F, Chang TMS. Cross-linked hemoglobin–superoxide dismutase-catalase scavenges oxygen-derived free radicals and prevents methemoglobin formation and iron release. *Biomater Artif Cells Immobil Biotechnol*. 1993; 21:609–622.
13. Carter P. Spectrophotometric determination of serum iron at the submicrogram level with a new reagent (ferrozine). *Anal Biochem*. 1971; 40:450–458. [PubMed: 5551554]
14. Chang, TMS. Hb corpuscles. Report of a research project of B.Sc. Honours Physiology. McGill University; 1957. p. 1-25. 1957. Medical Library, McGill University (also reprinted in Chang

- (TMS) J. Biomaterials, Artificial Cells and Artificial Organs 16:1–9, 1988 and also in Chang TMS (2007) monograph on Artificial Cells, World Scientific Publisher, Singapore)
15. Djordjevic L, Miller IF. Synthetic erythrocytes from lipid encapsulated Hb. *Exp Hematol.* 1980; 8:584. [PubMed: 7461058]
 16. Philips WT, Klpper RW, Awasthi VD, Rudolph AS, Cliff R, Kwasiborski VV, Goins BA. Polyethylene glyco-modified liposome-encapsulated Hb: a long circulating red cell substitute. *J Pharm Exp Ther.* 1999; 288:665–670.
 17. Kobayashi, K.Tsuchida, E., Horinouchi, H., editors. *Artificial Oxygen Carriers.* Springer-Verlag Publisher; 2005.
 18. Sakai H, Masada Y, Takeoka S, Tsuchida E. Characteristics of bovine Hb as a potential source of Hb vesicles for an artificial oxygen carrier. *J Biochem.* 2002; 131:611–617. [PubMed: 11927000]
 19. Chang TMS. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. *J Bioeng.* 1976; 1:25–32. [PubMed: 1052520]
 20. Yu WP, Chang TMS. Submicron biodegradable polymer membrane Hb nanocapsules as potential blood substitutes: a preliminary report. *Artif Cells Blood Substit Immobil Biotechnol, Int J.* 1994; 22:889–894.
 21. Yu WP, Chang TMS. Submicron biodegradable polymer membrane Hb nanocapsules as potential blood substitutes. *Artif Cells Blood Substit Immobil Biotechnol, Int J.* 1996; 24:169–184.
 22. Chang, TMS., Yu, WP. Nanoencapsulation of Hb and RBC enzymes based on nanotechnology and biodegradable polymer. In: Chang, TMS., editor. *Blood Substitutes: Principles, Methods, Products and Clinical Trials.* Vol. 2. Karger; Basel: 1998. p. 216-231.
 23. Chang TMS, Powanda D, Yu WP. Ultrathin polyethylene-glycol-poly lactide copolymer membrane nanocapsules containing polymerized Hb and enzymes as nanodimension RBC substitutes. *Artif Cells Blood Substit Immobil Biotechnol, Int J.* 2003; 31:231–248.
 24. Chang TMS. Artificial cells with cofactor regenerating multienzyme systems. *Methods in Enzymology.* 1985; 112:195–203. [PubMed: 4046849]
 25. Wong N, Chang TMS. Polyhemoglobin–fibrinogen: a novel blood substitutes with platelet-like activity for extreme hemodilution. *Artif Cells Blood Substit Biotechnol.* 2007; 35:481–489.
 26. Yu BL, Chang TMS. *In vitro* and *in vivo* effects of polyHb-tyrosinase on murine B16F10 melanoma. *Melanoma Res.* 2004; 14:197–202. 1. [PubMed: 15179188]
 27. Bucci E, Matheson B, Kwansa H, Koehler RC. Development of zero-link polymers of hemoglobin, which do not extravasate and do not induce pressure increases upon infusion. *Biotechnol.* 2007; 35(1):11–18.
 28. Tarasov E, Blaszk MM, LaMarre JM, Olsen KW. Synthesis of a hemoglobin polymer containing antioxidant enzymes using complementary chemistry of maleimides and sulfhydryls. *Artif Cells Blood Substit Biotechnol.* 2007; 35(1):31–43.

Fig. 1.

Factors that activate complement in the classical and alternate pathway as shown. (From [4] with copyright permission.)

Fig. 2.

Oxygen-Hb dissociation: 24 h of cross-linking with glutaraldehyde has only small effect on the Fig 4.8 Oxygen Dissociation curve of SF-Hb. PolyHb and PolyHb-SOD-CAT P_{50} values are 26.1 ± 0.2 mmHg and 24.7 ± 0.2 mmHg, respectively. SF-Hb P_{50} value is 27.8 ± 0.0 mmHg. All oxygen-Hb dissociation curves are presented as averages of 6 trials ($n=6$). (From [11] with copyright permission.)

Fig. 3. Absorbance spectra of PolyHb and PolyHb-SOD-CAT (10 μ M) following H_2O_2 addition of 0, 10, 100, and 500 μ M. (From [12] with copyright permission.)

Fig. 4.

(A) The release of iron, measured by ferrozine assay, from PolyHb (15 μM) or PolyHb-SOD-CAT (15 μM) incubated with H₂O₂ for 1 h at 37 °C. (B) Iron release from either PolyHb (15 μM) or PolyHb-SOD-CAT (15 μM) prepared with different CAT concentrations, following incubation with 250 μM H₂O₂. Error bars represent standard error of triplicate measurements. (From [12] with copyright permission.)

Fig. 5. Nanoencapsulation increases MetHb level. After this when incubated at 37 °C metHb increases quickly. Addition of a reducing agent, ascorbic acid prevents the increase in MetHb. Addition of glucose and NADH decreases MetHb further. (From [4] with copyright permission.)

Table 1

Molecular weight	MW component (%)	SOD activity (%)	Catalase activity (%)
<i>PolyHb-SOD-CAT sample</i>			
>450 kDa	77	83±3	82±2
100 to 450 kDa	16	7±2	11±1
<100 kDa	7	4±1	5±1
<i>PolyHb sample</i>			
>450 kDa	77	0	0
100 to 450 kDa	16	0	0
<100 kDa	7	0	0

Table 2**Characteristics**

Hb concentration:	10.97 g/dl (up to 15 g/dl)
Polymer concentration:	1.2 g/dl
Phospholipid concentration:	0.6 g/dl
Specific gravity (22 °C):	1.0047
Viscosity (37 °C):	3.7 to 3.8 cp
Bohr effect:	−0.22 to −0.24
Hill coefficient:	2.4 to 2.9
P_{50} :	26 mm Hg